Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer through a tissue sample test (biopsy) and are scheduled to have a PSMA PET scan (a type of imaging scan that looks for prostate cancer in the body).
- People who have the PSMA PET scan done before receiving any treatment for prostate cancer, including hormone therapy, radiation, or surgery.
- People who are able to provide a blood sample (about 10 mL) before any prostate cancer treatment begins and before any prostate biopsy takes place.
- People who are willing to have a prostate biopsy if their doctor recommends it, with the biopsy done after the blood sample is collected.
- People who are willing to sign a consent form agreeing to take part in the study.
- People aged 18 years or older.
Who may not be able to join:
- People who have already received any prostate cancer treatment — such as hormone therapy, radiation, chemotherapy, or surgery — before the initial PSMA PET scan.
- People whose blood sample was collected after a prostate biopsy had already been performed.
- People who have had another active cancer (other than certain common skin cancers) within the past two years.
- People whose blood sample is not of sufficient quality or volume for the required testing — for example, if the sample showed signs of breakdown or contained less than 8 mL of blood.
- People with serious health conditions that, in the trial doctor's judgement, could interfere with participation or create significant health risks.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 18700919857
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Specificity of the plasma exosomal RNA-based predictive signature for detecting PSMA PET-defined bone metastasis at a prespecified sensitivity threshold of ≥95%
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.